Stifel Maintains Buy on Zymeworks, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a Buy rating on Zymeworks (NASDAQ:ZYME) and raises the price target from $20 to $21.
August 02, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on Zymeworks and raises the price target from $20 to $21.
The Buy rating and increased price target from a reputable analyst at Stifel is likely to positively influence investor sentiment and drive short-term price appreciation for Zymeworks.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100